Clinical outcome after anti-tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long-term study.
Casanova MJ, Chaparro M, Nantes Ó, Benítez JM, Rojas-Feria M, Castro-Poceiro J, Huguet JM, Martín-Cardona A, Aicart-Ramos M, Tosca J, Martín-Rodríguez MDM, González-Muñoza C, Mañosa M, Leo-Carnerero E, Lamuela-Calvo LJ, Pérez-Martínez I, Bujanda L, Hinojosa J, Pajares R, Argüelles-Arias F, Pérez-Calle JL, Rodríguez-González GE, Guardiola J, Barreiro-de Acosta M, Gisbert JP; EVODIS Study Group*.
Casanova MJ, et al. Among authors: hinojosa j.
Aliment Pharmacol Ther. 2021 Jun;53(12):1277-1288. doi: 10.1111/apt.16361. Epub 2021 May 7.
Aliment Pharmacol Ther. 2021.
PMID: 33962482